{
  "id": 5499247,
  "title": "Top India Stock Picks From Jefferies Across Key Sectors",
  "url": "https://urgent.news/2026/09/04/top-india-stock-picks-from-jefferies-across-key-sectors",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-04T05:22:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/top-india-stock-picks-from-jefferies-across-key-sectors-93CH-4888828"
  },
  "original_language": "en",
  "account": "Jefferies has identified top stock picks across key sectors of India’s diverse market, pinpointing companies with promising growth potential and proven execution histories. Their recommendations span various industries, including energy, chemicals, real estate, consumer technology, healthcare, and pharmaceuticals, each backed by specific catalysts that could fuel their performance.\n\nIn the energy sector, JSW Energy is targeted for significant growth, with projected capacity to triple from 13.5 GW to 24.7 GW by FY30. The company currently has 13.6 GW under construction and 4.3 GW in various stages of development. Management forecasts achieving its FY27E guidance of 3 GW additions, emphasizing the reduction of merchant power's share from 8% in FY26 to just 2% by FY30E. This shift is expected to stabilize the EBITDA profile. With a $1 billion fundraising round, Jefferies anticipates a reduction in Net Debt to EBITDA to 5.0x by FY30E from 6.7x in FY26. The price target for JSW Energy is set at Rs720.\n\nFor the chemicals industry, Navin Fluorine International stands out, having secured multiple service contracts with committed revenues and stable margins. Their Bayer's Nubeqa product, protected by patents until 2033, is anticipated to see a 50% growth by CY2026. Additionally, the company's 2-phase immersion cooling technology for data centers, developed in collaboration with Chemours, boasts 40% less energy consumption. NFIL is poised to expand into the semiconductor chemical chain after doubling its AHF capacity to 60ktpa. Analysts see potential for a 23% Revenue CAGR and 31% EBITDA margin, projecting a 23% EPS CAGR over FY26-29E. The price target for Navin Fluorine International is Rs9,045.\n\nIn real estate, Lodha Developers is highlighted as India’s leading listed developer by land bank, with a capacity of 600 million square feet in development. They currently manage a 660-acre data center land bank, 20% of which has been sold to leading hyperscalers. Management aims to generate an annualized lease income of Rs20 billion from data centers over the next five years, with a steady PAT CAGR of 20% in the medium to long term. Net debt has consistently decreased, maintaining a gearing ratio of 0.2x as of June 2026. The firm is viewed as a prime investment for India’s digital consumption growth, with a BUY rating and a SoTP-based price target of Rs415.\n\nThe consumer technology sector is represented by Eternal Limited, a firm specializing in Zomato food delivery and Blinkit quick commerce. Zomato continues to deliver robust growth, with NOV growth exceeding 17% and improving profitability. Blinkit is the sole quick commerce player to have achieved profitability. Eternal Limited is considered the optimal play for India’s digital consumption growth, receiving a BUY rating with a SoTP price target of Rs415.\n\nTata Consumer Products is noted for its distinct advantage in having limited dependence on crude-linked inputs. The company’s core business in India continues to experience stable volume growth, while the growth portfolio shows strong double-digit expansion. With salience now exceeding 35% of the company’s business, recent price corrections in coffee should lead to margin expansion. Jefferies expects Revenue/EBITDA to grow at a CAGR of 10-14% over FY26-29E, with a SoTP-based price target of Rs1,450.\n\nFortis Healthcare is projected to add approximately 400 new beds in FY27 and 1,700 beds over the next four to five years. The company forecasts a revenue/EBITDA CAGR of 15%/20% for hospitals over the same period. In the diagnostics segment, Jefferies anticipates 10% revenue CAGR and 15% EBITDA CAGR. The parent company, IHH, plans to increase its stake to 51% from the current 31%. The price target for Fortis Healthcare is Rs1,125.\n\nGland Pharma, a wholly-owned subsidiary, has achieved sustainable EBITDA breakeven and exhibits a healthy demand outlook. The U.S. market is experiencing a resurgence, propelled by three to four differentiated product launches. Management’s guidance of 20% total sales growth over the next four years significantly exceeds consensus estimates. The current order book already supports a 15% constant-currency growth. Jefferies values Gland Pharma at 32x Sep-28 EPS, with a price target of Rs3,350.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}